In vitro combination effect of 5-fluorouracil and cisplatin on the proliferation, morphology and expression of Ki-67 antigen in human gastric cancer cells

Anti-Cancer Drugs

Volumn 8, Issue 10, 1997, Pages 1000-1006

  Imada, Toshio ^a   Rino, Yasushi ^a   Takahashi, Makoto ^a   Amano, Tomishige ^a   Kusada, Osamu ^b   Kitaura, Kozo ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Kyowa Analytical Research Center   (Japan)

Author keywords

5 Fluorouracil; Cisplatin; Combination effect; Gastric cancer

Indexed keywords

CISPLATIN; FLUOROURACIL; KI 67 ANTIGEN; PROPIDIUM IODIDE;

ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0031440821     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199711000-00011     Document Type: Article

References (29)

1. MacDonald JS. Cancer of the stomach. In: Cancer: principles & practice of oncology, 4th edn. Philadelphia, PA: Lippincott 1993: 838-48.
2. Lokich J, Bothe A, Fine N, Perri J. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981: 48: 2565-8.
3. Caballero GA, Ausman RK, Quebbeman EJ. Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep 1985: 69: 13-5.
4. Izumi M, Ohwara S, Shiozaki H, et al. Continuous infusion therapy with 5-fluorouracil for advanced or recurrent gastric cancer. J Jpn Soc Cancer Ther 1995: 30: 528-34.
5. Nakajima T, Fukami A, Takagi K, Kajitani T. Adjuvant chemotherapy with mitomycin C, and with a multi-drug combination of mitomycin C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jpn J Clin Oncol 1980: 10: 187-94.
6. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. Cancer 1983: 52: 1105-12.
7. Lisi VD, Cocconi G, Tonato M, Costanzo FD, Leonardi F, Soidani M. Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: A phase III trial of the italian clinical research oncology group (GOIRC). Cancer Treat Rep 1986: 70: 481-5.
8. Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989: 7: 1310-7.
9. Coombes RC, Schein PS, Chilvers CED, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990: 8: 1362-9.
10. Ohtsu A, Shimada Y, Yoshida S, et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994: 30A: 2091-3.
11. Mochizuki F, Tomioka K, Fujii M, et al. Clinical analysis of combination chemotherapy for advanced and recurrent gastric cancer with 5-fluorouracil (5-FU) and cisdiamminedichloroplatinum (CDDP). J Jpn Soc Cancer Ther 1995: 30: 1735-45.
12. Zaniboni A, Barni S, Labianca R, et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. Cancer 1995: 76: 1694-9.
13. Lisi VD, Cocconi G, Angelini F, et al. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. Cancer 1996: 77: 245-50.
14. Scanlon KJ, Newman RM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986: 83: 8923-5.
15. Etienne MC, Bernard S, Fischel JL, et al. Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br J Cancer 1991: 63: 372-7.
16. Kuroki M, Nakano S, Mitsugi K, et al. In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line. Cancer Chemother Pharmacol 1992: 29: 273-6.
17. Esaki T, Nanano S, Tatsumoto T, et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 1992: 52: 6501-6.
18. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993: 32: 167-72.
19. Saikawa Y, Kubota T, Kuo TH, et al. Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo. Anticancer Res 1993: 13: 461-4.
20. Esaki T, Nakano S, Masumoto N, Fujishima H, Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 1996: 65: 479-84.
21. Johnston PG, Geoffrey F, Drake J, Voeller D, Grem JL, Allegra CJ. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer 1996: 32A: 2148-54.
22. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988: 48: 589-601.
23. Gerdes J, Lemke H, Baisch H, Wacker HM, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984: 133: 1710-5.
24. Sasaki K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987: 133: 579-84.
25. Dengler WA, Schulte J, Berger DP, Mertelsmann R, Fiebig HH. Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anti-Cancer Drugs 1995: 6: 522-32.
26. Ozawa S, Sugiyama Y, Mitsuhashi J, Inaba M. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res 1989: 49: 3823-8.
27. Inaba M, Mitsuhashi J, Ozawa S. Kinetic analysis of 5-fluorouracil action against various cancer cells. Jpn J Cancer Res 1990: 81: 1039-44.
28. Tagawa Y, Kawazoe N, Sawai T, Yamaguchi S, Tomita M. Relationship between the Ki-67 nuclear antigen content and cell-cycle perturbation on WiDr cells treated with 5-FU. Human Cell 1993: 6: 121-5.
29. Sugamura K, Makino M, Shirai H, et al. Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. Cancer 1997: 79: 1-7.